MarketsStocksBALAXI
BA

BALAXI PHARMACEUTICALS LIMITED

NSE: BALAXI
Download Research Report7-page PDF
22.85
-1.68%
NSE · auto-updates while market open
Prev Close
₹52.93
Day High
₹23.70
Day Low
₹22.50
Mkt Cap
₹126 Cr
P / E
12.9
P / B
0.5
ROE
4.1%
52W High
₹55.64
52W Low
₹15.20
Key Metrics
Market Cap
₹126 Cr
P / E
12.91
P / B
0.51
EV / EBITDA
6.29
ROCE
6.7%
ROE
4.1%
Debt / Equity
0.09
Book Value
₹45.12
EPS
₹0.26
Div Yield
0.0%
Face Value
₹2
Promoter Holding
66.0%
Revenue · ₹ Cr
46
FY20
231
FY21
279
FY22
336
FY23
241
FY24
293
FY25
270
FY26
Net Profit · ₹ Cr
6
38
48
46
25
1
-2
FY20FY21FY22FY23FY24FY25FY26
EPS · ₹ per share
₹8.1
₹38.1
₹47.7
₹45.8
₹4.5
₹0.3
₹-2.3
FY20FY21FY22FY23FY24FY25FY26
P / E Ratio · price ÷ TTM EPS
Trading at 12.9× - 352% above its own 5-year median of 2.9×.
06121864240-15Jun 21Feb 23Oct 24Jun 26
P/E 12.9×Median 2.9×TTM EPS
Cash Flow Trend · ₹ Cr
34
29
FY22
6
−5
FY23
5
4
FY24
−35
 
FY25
−5
 
FY26
Operating cash flowFree cash flow (CFO − capex)Cash conversion: CFO = 5% of net profit (5y)
Q4 '26 snapshot
Sales
₹71 Cr
Operating profit
-
OPM
-
Net profit
₹1 Cr
EPS
₹0.11
Scorecard · 7 axes
Quality
Weak
41/100
Valuation
Strong
12.9×
Growth
Bad
-28.5%
Profitability
Weak
5.4%
Performance
Bad
-56.4%
Entry Point
Strong
41%
Red Flags
Strong
0 flags
Shareholding Pattern
66.0%Promoter
Promoter66.0%
FII1.7%
DII0.0%
Public32.3%
Quarterly Results · ₹ Cr
QuarterQ2 '25Q3 '25Q4 '25Q2 '26Q3 '26Q4 '26
Revenue77.38273.29176.26656.17572.54270.714
Net Profit4.5895.3638.6390.2090.3050.613
NPM %5.9%7.3%11.3%0.4%0.4%0.9%
AlertPre-trade